| Literature DB >> 29169337 |
Ke Chen1, Yu Pan1, Xiao-Long Liu1, Guang-Yi Jiang1, Di Wu1, Hendi Maher2, Xiu-Jun Cai3.
Abstract
BACKGROUND: Minimally invasive pancreatoduodenectomy (MIPD) has been gradually attempted. However, whether MIPD is superior, equal or inferior to its conventional open pancreatoduodenectomy (OPD) is not clear.Entities:
Keywords: Laparoscopy; Meta-analysis; Minimally invasive; Morbidity; Pancreaticoduodenectomy; Review; Robot
Mesh:
Year: 2017 PMID: 29169337 PMCID: PMC5701376 DOI: 10.1186/s12876-017-0691-9
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Fig. 1Flow chart of literature search strategies
Results of the meta-analysis
| Outcomes | No. of studies | Sample size | Heterogeneity ( | Overall effect size | 95% CI of overall effect |
| |
|---|---|---|---|---|---|---|---|
| MIPD | OPD | ||||||
| Operation time (min) | 12 | 518 | 1054 | <0.01, 96% | WMD = 99.4 | 46.0 ~ 152.8 | <0.01 |
| Blood loss (mL) | 9 | 408 | 845 | <0.01, 83% | WMD = −0.54 | −0.88 ~ −0.20 | <0.01 |
| Transfusion | 15 | 739 | 1527 | 0.25, 18% | RR = 0.73 | 0.57 ~ 0.94 | 0.02 |
| Time to oral intake (days) | 3 | 172 | 333 | 0.02, 73% | WMD = −0.86 | −1.90 ~ 0.18 | 0.11 |
| Hospital stay (days) | 11 | 402 | 829 | <0.01, 76% | WMD = −3.49 | −4.83 ~ −2.15 | <0.01 |
| Overall complications | 24 | 825 | 1496 | <0.01, 57% | RR = 0.89 | 0.78 ~ 1.02 | 0.10 |
| POPF | 25 | 853 | 1521 | 0.60, 0% | RR = 0.91 | 0.78 ~ 1.07 | 0.25 |
| Severe POPF | 21 | 983 | 2169 | 0.80, 0% | RR = 1.04 | 0.86 ~ 1.27 | 0.68 |
| DGE | 19 | 720 | 1349 | 0.81, 0% | RR = 0.70 | 0.53 ~ 0.94 | 0.02 |
| PPH | 10 | 427 | 839 | 0.46, 0% | RR = 1.18 | 0.79 ~ 1.78 | 0.42 |
| Reoperation | 14 | 449 | 817 | 0.49, 0% | RR = 1.02 | 0.70 ~ 1.49 | 0.92 |
| Readmission | 9 | 512 | 1219 | 0.46, 0% | RR = 1.16 | 0.96 ~ 1.40 | 0.13 |
| Mortality | 21 | 972 | 2158 | 0.99, 0% | RR = 0.81 | 0.51 ~ 1.30 | 0.39 |
| Retrieved lymph nodes | 11 | 421 | 995 | <0.01, 79% | WMD = 1.13 | −0.32 ~ 2.59 | 0.13 |
| R0 rate | 21 | 582 | 1554 | 0.13, 27% | RR = 1.06 | 1.00 ~ 1.12 | 0.04 |
Fig. 2Forest plot of the meta-analysis: operation time
Fig. 3Forest plot of the meta-analysis: estimated blood loss
Fig. 4Forest plot of the meta-analysis: transfusion
Fig. 5Forest plot of the meta-analysis: length of hospital stay
Surgical complications of MIPD in reviewed studied (list by constituent ratio)
| Complications | Total events ( |
|---|---|
| POPF | 372 (37.1%) |
| DGE | 255 (25.4%) |
| PPH | 141 (14.1%) |
| Fluid collection/abscess | 84 (8.4%) |
| Wound complications | 60 (6.0%) |
| Bile leakage | 56 (5.6%) |
| Ileus | 17 (1.7%) |
| Chyle leakage | 5 (0.5%) |
| Gastrointestinal anastomotic leakage | 4 (0.4%) |
| Peptic ulcer | 3 (0.3%) |
| Other | 6 (0.6%) |
Other complications included colitis (n = 1), colon perforation (n = 1), bowel ischemia (n = 1), PV thrombus (n = 1), dumping syndrome (n = 1), trocar site bleeding (n = 1)
Medical complications of MIPD in reviewed studied (list by constituent ratio)
| Complications | Total events ( |
|---|---|
| Respiratory | 98 (49.2%) |
| Cardiovascular | 69 (34.7%) |
| Renal | 18 (9.0%) |
| Deep venous thrombosis | 10 (5.0%) |
| Other | 4 (2.0%) |
Respiratory: included pulmonary infection, pneumonias, pleural effusion, pulmonary embolism, pulmonary edema, atelectasis, lung failure, ARDS; Cardiovascular: included heart failure, myocardial infarction, arrhythmia, hypotension, acute coronary syndrome; Renal: included renal failure, urinary infection, urinary retention, renal insufficiency; other complications included thrombocytopenia (n = 1), anemia (n = 1), hepatic insufficiency (n = 2)
Fig. 6Forest plot of the meta-analysis: overall POPF
Fig. 7Forest plot of the meta-analysis: retrieved lymph nodes
Summary of Recurrence and Long-term Survivals
| Author | Group | Malignant case | Follow-up (month) | Recurrence | Survival (time: month; rate: %) |
|---|---|---|---|---|---|
| Zureikat [ | MIPD | 12 | 9.5(4–21) | 1 | NR |
| Croome [ | MIPD | 108 | 16.5 | 44 | MOS: 25.3 m |
| OPD | 214 | 15.1 | 113 | MOS: 21.8 m | |
| Hakeem [ | MIPD | 12 | 46.8(13.0–73.7) | 2 | 1, 3, 5y–DFS: 100; 92, 83, 5y–OS: 100, 83, 83 |
| OPD | 12 | 56.0(1.0–97.4) | 2 | 1, 3, 5y–DFS: 100; 92, 75, 5y–OS: 75, 58, 50 | |
| Song [ | MIPD | 11 | NR | NR | 5y–OS: 53.6 |
| OPD | 222 | NR | NR | 5y–OS: 28.8 | |
| Chen [ | MIPD | 19 | 22 ± 10 | NR | MDFS: 14.0 m; MOS: 23.0 m |
| OPD | 39 | 21 ± 8 | NR | MDFS: 13.0 m; MOS: 22.0 m | |
| Delitto [ | MIPD | 52 | NR | NR | MOS: 27.9 m; MOS: 20.7 m* |
| OPD | 50 | NR | NR | MOS: 23.5 m; MOS: 21.1 m* | |
| Palanivelu [ | MIPD | 49 | 36.5 | NR | MOS: 49 m; 5y–OS: 30.4 |
| Pugliese [ | MIPD | 11 | 32(12–45) | 7 | MDFS: 11 m; MOS: 18 m |
| Senthilnathan [ | MIPD | 130 | 24 | NR | MOS: 33 m; 5y–OS:29.4 |
| Wang [ | MIPD | 16 | 18(8–48) | 10 | MDFS: m16; MOS: 19 m |
| Coratti [ | MIPD | 41 | 15.8(2–47) | 12 | MOS: 40 m; 1, 2, 3y–OS: 81, 69, 55 |
| Kantor [ | MIPD | 828 | 18 | NR | MOS: 20.7 m |
| OPD | 7385 | NR | MOS: 20.9 m | ||
| Stauffer [ | MIPD | 58 | 19.6 ± 17.4 | NR | MOS: 18.5 m; 1, 2, 3, 4, 5y–OS: 66.5, 43.3, 43.3, 38.5, 32.1 |
| OPD | 193 | 24.5 ± 27.4 | NR | MOS: 20.3 m; 1, 2, 3, 4, 5y–OS: 67.5, 40.2, 24.3, 17.1, 15.3 |
Follow-up time were shown as median (range) or median only; DFS: disease-free survival rate; OS: overall survival rate; MDFS: median disease-free survival time; MOS: median overall survival time; y: year; *special for PDAC; NR: not report
Fig. 8Funnel plot of the overall POPF rates